Rabeprazole Sodium Market Future Growth Analysis by 2020-2024|Leading Players: JSN Chemicals, Jubilant Pharma, Smaart Pharmaceutticals, ASN Corporation
Overview of Global Rabeprazole Sodium Market:
Rabeprazole sodium (Aciphex) is a proton pump inhibitor (PPI) to reduce stomach acid and is used for the treatment of gastroesophageal reflux disease (GERD), duodenal ulcers, and used in combination with antibiotics to treat Helicobacter pylori (H. pylori) bacterial infections in the stomach.
The report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Rabeprazole Sodium market with different perspectives for the purpose of providing a detailed, informative, and accurate analysis of regional growth, competition, market segmentation, and other important aspects.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/268526 .
Growth in the historic period resulted from economic growth in emerging markets, the rise in awareness of the benefits and developed nations towards Rabeprazole Sodium costs and an increase in the number of proton pump inhibitor (PPI) to reduce stomach acid.
Product Type Segmentation:
The Rabeprazole Sodium market have different product type such as Rabeprazole Sodium Monohydrate and Rabeprazole Sodium Crystalline. Rabeprazole Sodium market product type gives proton pump inhibitor (PPI) to reduce stomach acid.
Increasing instances across various sectors such as Gastroesophageal Reflux Disease Treatment, Duodenal Ulcer Treatment and Others are raising the need of healthcare institutes, thereby raising the demand for Rabeprazole Sodium market. This help in the profitable growth of the Global Rabeprazole Sodium market in upcoming year.
Segmentation by Regions:
The Rabeprazole Sodium market in North America has created proton pump inhibitor (PPI) to reduce stomach acid to help patients in the world. It was followed by Western Europe, China, Japan, Southeast Asia, India and Central & South America regions. Asia Pacific is expected to record higher growth rate in Rabeprazole Sodium Market during the forecast year.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Global Rabeprazole Sodium Market Report 2020” @ https://www.businessindustryreports.com/buy-now/268526/single .
Top Leading Key Manufacturers are: JSN Chemicals, Jubilant Pharma, Smaart Pharmaceutticals, Shanghai Pharma Group Changzhou Kony Pharmaceutical, ASN Corporation, Intas, Sterile India, Zhejiang Yongtai Technology, Enal Drugs Private Limited, Syntech Chem and Pharm.New product launches and continuous technological innovations are the key strategies adopted by the major players.
Top Industry News:
Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19 on 12 May, 2020 -- Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India. These countries consist of nearly all low-income and lower middle-income countries, as well as several upper-middle and high-income countries that face significant obstacles to healthcare access. Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries.
Commenting on the partnership, Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Limited, said, “We are very happy to strengthen our partnership with Gilead to license remdesivir, which, based on initial data, shows promise to be a potential therapy for Covid-19, a pandemic creating unprecedented health and economic crisis globally. We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s Active Pharmaceutical Ingredient (“API”) in-house helping its cost effectiveness and consistent availability.”
Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by USFDA to treat Covid-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease. The EUA is based on available data from two global clinical trials – US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead’s global Phase 3 study evaluating remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of remdesivir as a treatment for COVID-19. Remdesivir remains an investigational drug and has not been approved by USFDA.
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/268526 .
Major Points in Table of Contents:
1 Rabeprazole Sodium Product Definition
2 Global Rabeprazole Sodium Market Manufacturer Share and Market Overview
2.1 Global Manufacturer Rabeprazole Sodium Shipments
2.2 Global Manufacturer Rabeprazole Sodium Business Revenue
2.3 Global Rabeprazole Sodium Market Overview
2.4 COVID-19 Impact on Rabeprazole Sodium Industry
3 Manufacturer Rabeprazole Sodium Business Introduction
3.1 JSN Chemicals Rabeprazole Sodium Business Introduction
3.1.1 JSN Chemicals Rabeprazole Sodium Shipments, Price, Revenue and Gross profit 2014-2019
3.1.2 JSN Chemicals Rabeprazole Sodium Business Distribution by Region
3.1.3 JSN Chemicals Interview Record
3.1.4 JSN Chemicals Rabeprazole Sodium Business Profile
3.1.5 JSN Chemicals Rabeprazole Sodium Product Specification
3.2 Jubilant Pharma Rabeprazole Sodium Business Introduction
3.2.1 Jubilant Pharma Rabeprazole Sodium Shipments, Price, Revenue and Gross profit 2014-2019
3.2.2 Jubilant Pharma Rabeprazole Sodium Business Distribution by Region
3.2.3 Interview Record
3.2.4 Jubilant Pharma Rabeprazole Sodium Business Overview
3.2.5 Jubilant Pharma Rabeprazole Sodium Product Specification
3.3 Smaart Pharmaceutticals Rabeprazole Sodium Business Introduction
3.3.1 Smaart Pharmaceutticals Rabeprazole Sodium Shipments, Price, Revenue and Gross profit 2014-2019
3.3.2 Smaart Pharmaceutticals Rabeprazole Sodium Business Distribution by Region
3.3.3 Interview Record
3.3.4 Smaart Pharmaceutticals Rabeprazole Sodium Business Overview
3.3.5 Smaart Pharmaceutticals Rabeprazole Sodium Product Specification
3.4 Shanghai Pharma Group Changzhou Kony Pharmaceutical Rabeprazole Sodium Business Introduction
3.5 ASN Corporation Rabeprazole Sodium Business Introduction
3.6 Intas Rabeprazole Sodium Business Introduction
………………. Request free sample to get a complete Table of Content
BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.
Business Industry Reports
Pune – India
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rabeprazole Sodium Market Future Growth Analysis by 2020-2024|Leading Players: JSN Chemicals, Jubilant Pharma, Smaart Pharmaceutticals, ASN Corporation here
News-ID: 2083316 • Views: 947
More Releases from Business Industry Reports
2020-2025 Neoantigen Targeted Therapies Market to witness astonishing growth wit …
Global Neoantigen Targeted Therapies Market Synopsis: The report covers a forecast and an analysis of the Neoantigen Targeted Therapies Market on a global and regional level. The study provides historical data for 2015, 2016, 2017 and 2018 along with a forecast from 2020 to 2025 based on revenue (USD Million) and volume (Kilotons). The study includes drivers and restraints of the Neoantigen Targeted Therapies Market along with the impact they have
Outstanding Scope of Nasojejunal Tube Market is Estimated to Grow Incredible CAG …
Overview of Global Nasojejunal Tube Market: This report provides in-depth study of “Global Nasojejunal Tube Market 2020” using SWOT analysis i.e. Strength, Weakness, Opportunities, and Threat to the organization. The Nasojejunal Tube Market report also provides an in-depth survey of key players in the market organization. The 'Global Nasojejunal Tube Industry, Market Research Report' is a professional and in-depth study on the current state of the global Nasojejunal Tube Market with a
Huge Investment in mTOR Inhibitors Market Expected to Witness the Highest Growth …
Global mTOR Inhibitors Market Synopsis: The exclusive research report on the Global mTOR Inhibitors Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mTOR Inhibitors Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. According to the market research study, Mammalian Target Of Rapamycin (mTOR) is
SWOT Analysis of mRNA Treatment Market Excessive Growth Opportunities Estimated …
The exclusive research report on the Global mRNA Treatment Market 2020 examines the market in detail along with focusing on significant market dynamics for the key players operating in the market. Global mRNA Treatment Industry research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe. Overview of Global mRNA Treatment Market: This report studies the Global mRNA Treatment Market over the forecast
More Releases for Rabeprazole
Proton Pump Inhibitors Market is expected to register a CAGR of 5% during the fo …
Market Analysis: United States Leads the Market in North America The United States proton pump inhibitors market held the largest market share in 2017 in North America due to the growing prevalence of gastrointestinal disorders, and is likely to contribute towards the growth of the proton pump inhibitors market. Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16845 Note: “If this link doesn’t work in Internet Explorer, kindly try pasting it in other browsers.” Proton
Ranitidine Market Groth Factors 2026 - GlaxoSmithKline, Boehringer Ingelheim, St …
Ranitidine is a histamine type 2 (H2) receptor blocker drug available by prescription as well as over-the-counter (OTC). Ranitidine is used in treatment of intestinal & stomach ulcers, gastroesophageal reflux disease (GERD), and erosive esophagitis, and Zollinger-Ellison syndrome. Stomach ulcer or peptide ulcer causes open sores in the inner lining of stomach and upper portion of small intestine. Ranitidine helps to reduce excessive acid production in patient’s stomach. Increasing prevalence
Proton Pump Inhibitors Market to Witness Comprehensive Growth by 2024
Proton pump inhibitors are a group of medicines that reduces the gastric acid secretion in the linings of the stomach. They block the enzyme process in the gastric system that actively transports gastric acid from parietal cells to the gastrointestinal lumen in the form of hydrogen–potassium adenosine triphosphate (proton pump). Proton pump inhibitors are used to relieve the symptoms of gastro-esophageal reflux diseases (GERD), peptic ulcers, dyspepsia, gastritis, and other
Global Proton Pump Inhibitors Market Outlook 2018-2025 Pfizer, Eli Lilly, AstraZ …
A detailed market study on "Global Proton Pump Inhibitors (PPIs) Market" examines the performance of the Proton Pump Inhibitors (PPIs) market. It encloses an in-depth Research of the Proton Pump Inhibitors (PPIs) market state and the competitive landscape globally. This report analyzes the potential of Proton Pump Inhibitors (PPIs) market in the present and the future prospects from various angles in detail. The Global Proton Pump Inhibitors (PPIs) Market 2018 report
Barrett’s Esophagus Market Progresses for Huge Profits During 2017 - 2025
Barrett’s esophagus is also termed as columnar epithelium lined lower esophagus or Barrett syndrome. This disorder is an irregular change in the internal lining of oesophagus (lower portion). The cells of the esophagus (stratified squamous) are replaced by the cells of the stomach (goblet cells). This occurs due to the action of stomach acids (chronic acids). If the ring of muscles at the lower portion of oesophagus does not close
Proton Pump Inhibitors (PPIs) Report on Global and United States Market, Status …
"The Report 2017-2022 Proton Pump Inhibitors (PPIs) Report on Global and United States Market, Status and Forecast, by Players, Types and Applications provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" This report studies the Proton Pump Inhibitors (PPIs) market status and outlook of global and United States, from angles of players, regions, product types and end industries; this report analyzes the top